Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness

Purpose To evaluate biomarkers involved in biological pathways for prostate cancer (PCa) progression, measured in biopsy specimens, in order to distinguish patients at higher risk for fatal PCa and thus improve the initial management of disease.